Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.41 USD | 0.00% | +8.20% | +31.31% |
May. 13 | Oppenheimer Adjusts Achieve Life Sciences Price Target to $11 From $18, Maintains Outperform Rating | MT |
May. 09 | Transcript : Achieve Life Sciences, Inc., Q1 2024 Earnings Call, May 09, 2024 |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 186M |
---|---|---|---|---|---|
Net income 2024 * | -34M | Net income 2025 * | -39M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-4.89
x | P/E ratio 2025 * |
-5.68
x | Employees | 22 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.31% |
Latest transcript on Achieve Life Sciences, Inc.
1 week | +8.20% | ||
Current month | +23.23% | ||
1 month | +19.16% | ||
3 months | +36.62% | ||
6 months | -0.55% | ||
Current year | +31.31% |
Managers | Title | Age | Since |
---|---|---|---|
John Bencich
CEO | Chief Executive Officer | 47 | 14-07-31 |
Richard Stewart
CHM | Chairman | 65 | 15-04-30 |
Cindy Jacobs
PSD | President | 66 | 08-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Vaughn Himes
BRD | Director/Board Member | 63 | 22-03-13 |
Thomas King
BRD | Director/Board Member | 69 | 23-03-28 |
Cindy Jacobs
PSD | President | 66 | 08-07-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 5.41 | 0.00% | 163,176 |
24-05-23 | 5.41 | +5.05% | 108,309 |
24-05-22 | 5.15 | 0.00% | 52,887 |
24-05-21 | 5.15 | +1.78% | 96,508 |
24-05-20 | 5.06 | +1.20% | 57,303 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+31.31% | 186M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- ACHV Stock